αααααβααΎαHTD β’ FRA
add
Corcept Therapeutics Inc
29.25β¬
2 ααααΆ, 8:21:17 AM ααααβααα +1 · EUR · FRA · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
ααΆαβα αα»αααΌααααααααααΆαα
α»ααααααΈαα
DEααΆαααΈααααΆααααΆααααααΆααα
α’αΆαααα·α
αα·αααΈαα»α
67.62β¬
α
αααααααααααα
29.25β¬ - 29.25β¬
α
ααααααα½αααααΆαα
α»αααααα
29.25β¬ - 105.30β¬
ααΎαβαα»αβααΈααααΆα
3.66Β αααΈααΆα USD
ααα ααα½αααΌαααααα
17.00
α’αα»ααΆα P/E
-
αα·αααααβααΆαααΆα
-
ααΆααααααΌαα
αααα
NASDAQ
αααα»αβααααααΆαβ
MSN
1 ααααβαα»α
Stocks making big moves yesterday: FuelCell Energy, Corcept, and PacBio
7.93%
8.09%
50.42%
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
| (USD) | αααααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌα | 207.64Β ααΆα | 13.75% |
α
αααΆαααααα·ααααα·ααΆα | 192.82Β ααΆα | 44.89% |
α
αααΌααα»ααα | 19.67Β ααΆα | -58.34% |
ααααΆααα
αααααα»ααα | 9.47 | -63.38% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | 0.16 | -60.98% |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | 10.51Β ααΆα | -77.60% |
α’ααααΆαααααααααΆαααααα·αααααΆα | -29.03% | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
| (USD) | αααααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 421.68Β ααΆα | 10.87% |
ααααααααα»α | 823.61Β ααΆα | 5.02% |
ααΆαααα½ααα»αααααΌαααα»α | 191.70Β ααΆα | 31.83% |
ααΌαβααααα»α | 631.90Β ααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 105.19Β ααΆα | β |
ααααααααααΉαααααα
| 11.25 | β |
ααα
ααααααΎαααααα | 3.14% | β |
ααα
ααααααΎααΎααα»α | 3.99% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
| (USD) | αααααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌααα»ααα | 19.67Β ααΆα | -58.34% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | 54.48Β ααΆα | -25.67% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | 14.64Β ααΆα | 133.26% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | -46.41Β ααΆα | -120.05% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | 22.39Β ααΆα | 157.36% |
ααα αΌαααΆα
αααααΆααααααα | 38.75Β ααΆα | -44.81% |
α’αααΈ
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD. Wikipedia
ααΆααααααΎαα‘αΎα
13 α§αααΆ 1998
ααΆαα·ααΆαααβαααααΆα
αααααβαααααΆα
αα»ααααα·α
500
